FDA approval ≠ commercial success.

 

Challenge:

​For medtech innovators, securing regulatory clearance is only the beginning. Today’s environment makes it harder than ever to reach and influence the physicians and health systems that drive adoption:

​

• Shrinking HCP access and hospital gatekeeping make traditional sales models inefficient.

• Fragmented purchasing processes complicate B2B decision-making.

• Competitive noise can bury breakthrough devices before they find their champion KOLs.

• Limited launch planning often leads to stalled adoption curves.

​​

Solution:

SkyBridge transforms medtech commercialization by combining clinical credibility with market precision.

​

Our services include:

​

• Strategic Launch Planning: Clear timelines, resource mapping, and cross-functional alignment to ensure your device reaches the right hands at the right time.

• KOL Mapping & Activation: Identifying and mobilizing influential clinicians and thought leaders to champion adoption.

• Access Strategy: Tailored approaches to navigate IDNs, GPOs, and hospital systems for faster procurement.

• Omnichannel HCP Engagement: Modern tactics that extend beyond reps — blending digital touchpoints, peer-to-peer channels, and education platforms.

​

Proof:

• 2.5× increase in qualified surgeon leads within six months of launch for a Class II device.

• KOL engagement programs led to 4 major IDN contracts secured ahead of schedule.

​​

Case Study: For a novel imaging technology, SkyBridge orchestrated a 90-day KOL acceleration program that resulted in 65% faster adoption compared to baseline launches.

 

“They understood our clinical story — and built a launch engine around it. We went from invisible to indispensable in key accounts.”  VP, Marketing, Medtronic